|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
An Open, Positive Drug-controlled, Parallel-group, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flunotinib Maleate Tablets in the Treatment of Patients With Intermediate- and High-risk Myelofibrosis
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose fruquintinib maleate tablet group, high-dose fruquintinib maleate tablet group, or the ruxolitinib tablet group. Stratification factors include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
A randomized, double-blind, placebo-controlled, dose-escalating, single-dose, oral phase I clinical study of the safety, tolerability, and pharmacokinetics of flunotinib maleate tablets in healthy adult subjects in China.
100 项与 FLT3 x CDK6 x JAK2 相关的临床结果
100 项与 FLT3 x CDK6 x JAK2 相关的转化医学
0 项与 FLT3 x CDK6 x JAK2 相关的专利(医药)